Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536

epoetin alfa
cancer
vasectomy
erythropoietin
  • 53 views
  • 26 Mar, 2021
  • 7 locations
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US  

luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA na├»ve subjects who require RBC transfusions.   The

epoetin alfa
cancer
vasectomy
erythropoietin
  • 5134 views
  • 19 Apr, 2021
  • 15 locations
A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following subjects: Subjects receiving luspatercept on a parent protocol

ace-536
cancer
hysterectomy
growth factor
luspatercept
  • 82 views
  • 27 Jan, 2021
  • 125 locations
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without RBC-transfusion

luspatercept
vasectomy
polycythemia
myeloproliferative disorder
anemia
  • 384 views
  • 07 May, 2021
  • 26 locations
Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Na ve Subjects Who Require Red Blood Cell Transfusions

Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536

anemia
bone marrow procedure
blood transfusion
cancer
erythropoietin
  • 289 views
  • 12 May, 2021
  • 259 locations
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF

  • 0 views
  • 10 May, 2021
  • 156 locations
A Safety Trial of Fedratinib in Subjects With DIPSS Intermediate or High-Risk Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia

Luspatercept for subjects with anemia. The primary objective of the main study is to evaluate the percentage of subjects with at least a 35% reduction in spleen size and one of the secondary objectives

thrombocytopenia
polycythemia
anemia
essential thrombocythemia
fedratinib
  • 72 views
  • 01 Feb, 2021
  • 40 locations
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Practice (GCP) and applicable regulatory requirements. This is a Phase 2, multicenter, single-arm study to evaluate the efficacy, safety and Pharmacokinetics (PK) of luspatercept (ACE-536) for the

anemia
bone marrow procedure
cancer
blood transfusion
  • 0 views
  • 18 Mar, 2021
  • 15 locations